The objective of this analysis was to examine the impact of ustekinumab on health related quality of life (HRQoL) in psoriasis patients. METHODS: 766 patients were enrolled in the PHOENIX I trial. Patients were randomized to placebo, ustekinumab 45 mg, or ustekinumab 90 mg. Patients received ustekinumab at baseline, week 4, and q12w thereafter. Patients randomized to placebo received placebo at baseline and week 4, and ustekinumab 45 mg or 90 mg after cross-over at week 12. HRQoL were assessed using the SF-36 and Dermatology Life Quality Index (DLQI). RESULTS: Baseline SF-36 and DLQI scores were similar among treatment groups with a mean PCS score of 47.9, mean MCS score of 49.8, and mean DLQI score of 11.5. Compared with the placebo group, patients in each ustekinumab group had significantly greater improvements from baseline in both the PCS (2.0 and 3.2, vs. -0.5, p < 0.001) and MCS scores (2.1 and 2.5 vs. -1.3, p < 0.001) at week 12. All 8 domains of the SF-36 showed statistically significant improvements (p < 0.05) in the combined ustekinumab group versus placebo at week 12. At week 12, the mean change from baseline in DLQI was -8.0 for the 45 mg group and -8.7 for the 90 mg group versus -0.6 for the placebo group (each p < 0.001 vs. placebo). A greater proportion of patients in each ustekinumab group than in the placebo group achieved a clinically meaningful improvement in PCS and MCS scores (Ն5-point improvement), and a DLQI score of 0 or 1 at week 12. These improvements observed in the ustekinumab groups were maintained through week 40. Patients in the placebo group who crossed-over to ustekinumab at week 12 achieved improvements in PCS, MCS and DLQI scores at week 40 that were similar in magnitude to those observed in patients initially randomized to ustekinumab. CONCLUSIONS: Ustekinumab treatment significantly improves overall and diseasespecific quality of life in moderate to severe psoriasis patients. and a specific scale (DLQI-Dermatology Life Quality Index) were filled in by each patient when they arrived at the Avène hydrotherapy center (consultation on arrival), at the end of the thermal therapy (week 3), but also at 3 and 6 months after the end of the therapy. RESULTS: These results took into account the 262 questionnaires from patients suffering from psoriasis who filled in the selfquestionnaires on arrival. The average age of the subjects was 52.2 Ϯ 13.8 years. The gender ratio was in favour of men (55.3% vs 44.7%). The average age of the subjects at the time of diagnosis was 32.1 Ϯ 16.9 years. 66.0% of the subjects considered that their dermatosis had deteriorated "their daily life", 49.6% "their health" and 49.2% "their leisure activities". Following the 3 weeks of treatment these feelings had strongly diminished, there were respectively only 35.2%, 26.6% and 30.5% who thought so. The DLQI score on arrival was 26.1 Ϯ 20.2; following therapy it was 10.0 Ϯ 10.5. The evaluation of the DLQI score was compared to the score obtained on arrival, showing a significant improvement in quality of life at 3 weeks, sustained improvement at 3 months and perpetuation of the effect at 6 months (p < 0.05). These results show a significant improvement in the mental dimension of the SF-12 (MCS-12 = 39.0 on arrival to 42.5 at following therapy). CONCLUSIONS: This study confirms the alteration in the quality of life of patients suffering from psoriasis and its impact on daily life. The results confirm the improvement in the patients' quality of life following the therapy, sustained improvement at 3 months, and perpetuation at 6 months.
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and a specific scale (DLQI-Dermatology Life Quality Index) were filled in by each patient when they arrived at the Avène hydrotherapy center (consultation on arrival), at the end of the thermal therapy (week 3), but also at 3 and 6 months after the end of the therapy. RESULTS: These results took into account the 262 questionnaires from patients suffering from psoriasis who filled in the selfquestionnaires on arrival. The average age of the subjects was 52.2 Ϯ 13.8 years. The gender ratio was in favour of men (55.3% vs 44.7%). The average age of the subjects at the time of diagnosis was 32.1 Ϯ 16.9 years. 66.0% of the subjects considered that their dermatosis had deteriorated "their daily life", 49.6% "their health" and 49.2% "their leisure activities". Following the 3 weeks of treatment these feelings had strongly diminished, there were respectively only 35.2%, 26.6% and 30.5% who thought so. The DLQI score on arrival was 26.1 Ϯ 20.2; following therapy it was 10.0 Ϯ 10.5. The evaluation of the DLQI score was compared to the score obtained on arrival, showing a significant improvement in quality of life at 3 weeks, sustained improvement at 3 months and perpetuation of the effect at 6 months (p < 0.05). These results show a significant improvement in the mental dimension of the SF-12 (MCS-12 = 39.0 on arrival to 42.5 at following therapy). CONCLUSIONS: This study confirms the alteration in the quality of life of patients suffering from psoriasis and its impact on daily life. The results confirm the improvement in the patients' quality of life following the therapy, sustained improvement at 3 months, and perpetuation at 6 months. and a specific scale (DLQI-Dermatology Life Quality Index) were filled in by each patient when they arrived at the Avène hydrotherapy center (consultation on arrival), at the end of the thermal therapy (week 3), but also at 3 and 6 months after the end of the therapy. RESULTS: These initial results took into account the 174 questionnaires from patients suffering from atopic dermatitis. The average age of the subjects was 36.4 Ϯ 14.7 years. The gender ratio was largely in favour of women (70.1% vs 29.9%). The median age of the subjects at the time of diagnosis was 16.0 years. Women were diagnosed earlier than men, with a median diagnosis age of 8.0 years for women and 20 years for men. 72.1% of subjects considered that their dermatosis had deteriorated "their daily life", 58.9% "their health" and 60.0% "their leisure". Following the 3 weeks of therapy these feelings had strongly diminished, and respectively only 44.3%, 34.8% and 35.3% thought so. The DLQI score on arrival was 32.4 Ϯ 22.7 The evaluation of the DLQI score was compared to the DLQI score obtained on arrival, showing a significant improvement in quality of life at 3 weeks sustained improvement at 3 months and perpetuation of the effect at 6 months. No significant improvement in either the mental dimension or the physical dimension of the SF-12 were observed. CONCLUSIONS: This study confirms the alteration in the quality of life of patients suffering from atopic dermatitis and its impact on daily life. The results confirm the improvement in the patients' quality of life following the therapy, sustained improvement at three months, and perpetuation at six months.
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Boussetta S, Taieb C Pierre Fabre, Boulogne, France OBJECTIVES: The objective of this project was to conduct a cross-evaluation of the quality of life of patients suffering from psoriasis compared with those suffering from atopic dermatitis. METHODS: A generic scale (SF-12), a specific scale (DLQI-Dermatology Life Quality Index) and a daytime sleepiness evaluation questionnaire (Epworth scale) were completed by each patient when they arrived at the Avène Hydrotherapy center. RESULTS: For the population analysed (n = 460), the average age was respectively 37.5 Ϯ 14.9 years for patients suffering from atopic dermatitis (n = 175) compared with 53.7 Ϯ 14.0 years fro the patients with psoriasis (n = 279). The gender ratio was opposite, in favour of women for atopic dermatitis (70.1%) and men for psoriasis (55.3%). The DLQI score was 29.7 Ϯ 19.8 for patients suffering from atopic dermatitis and 27.2 Ϯ 19.2 for patients with psoriasis. The SF-12 mental dimension of patients suffering from atopic dermatitis were more altered than that of patients with psoriasis (38.0 Ϯ 6.5 versus 39.5 Ϯ 6.3). Patients with psoriasis were significantly more physically affected than atopic patients (physical dimension component of 44.4 Ϯ 6.7 in patients with psoriasis compared to 45.6 Ϯ 5.9 in atopic patients). Patients suffering from atopic dermatitis felt that their disease had significantly more often deteriorated their health than patients with psoriasis (with respectively 58.4% versus 49.5%), but also their relationships with their children and with the rest of their family. CONCLUSIONS: These initial results showed an alteration in the quality of life of patients with psoriasis and patients suffering from atopic dermatitis and the impact of 2 dermatoses on daily life. Patients with psoriasis were more affected physically, unlike the atopic patients, for whom the suffering was more mental. This notion also occurs with the feeling of a greater deterioration of their relationship with their children or families in atopic patients in comparison with psoriasis patients. Pierre Fabre, Boulogne, FRANCE, France OBJECTIVES: Evaluate QoL and self-perceived stress in a population with atopic dermatitis. METHODS: For 5 consecutive days, 5 dermatology departments in France handed out selfperceived stress (PCV-Metra) and QoL questionnaires (SF12) to patients attending their outpatient clinics. RESULTS: Of a total 658 adult patients who attended an appointment and responded during these 5 days, 10.5% presented with atopic dermatitis diagnosed by the dermatologist. Mean patient age was 35.6 Ϯ 17.0 years with more women than men (53.5% vs 46.6%). 41.1% had suffered from atopic dermatitis for less than one year and 25.5% for 5 years and more). One in two patients had made an appointment with their dermatologist because their atopic dermatitis had worsened. The self-perceived stress level was 9.1 Ϯ 4.3 and a sex-related bias in favour of women (10.3 Ϯ 4.7 vs 7.7 Ϯ 3.3, p = 0.004). Patients who had suffered from dermatosis for more than 5 years had a self-perceived stress level of 11.6 Ϯ 3.8 vs 7.7 Ϯ 3.7 in patients with less than 5 years. In addition, patients seeing their dermatologist because their condition had worsened had a self-perceived stress level of 10.4 Ϯ 4.0 vs 9.1 Ϯ 4.4 in patients consulting for another reason. The SF12 mental component score was 46.2 Ϯ 10.6 in patients with recently diagnosed atopic dermatitis (not more than 5 years) vs 41.3 Ϯ 8.6 in those with more than 5 years. CON-CLUSIONS: The age of the atopic dermatitis (more or less than 5 years) has a statistically significant impact on the self-perceived stress level (p = 0.04). Neither sex, date of diagnosis, or exacerbation of the atopic dermatitis had an impact on SF12 mental or physical component scores. Atopic patients seem to suffer from chronic stress related to the chronic nature of the dermatosis, probably caused by exhaustion and known changes occurring in the hypothalamus-pituitary axis.
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PSS46 MELANOTIC TUMOURS: EVALUATION OF SELF-PERCEIVED STRESS AND QUALITY OF LIFE
Boussetta S
1 , Taieb C 2 1 Pierre Fabre, Boulogne, France, 2 Pierre Fabre, Boulogne, FRANCE, France OBJECTIVES: Evaluate QoL and self-perceived stress in a population with melanotic tumours. METHODS: For 5 consecutive days, 5 dermatology departments in France handed out self-perceived stress (PCV-Metra) and QoL questionnaires (SF12) to patients attending their outpatient clinics. RESULTS: Of a total 658 adult patients who attended an appointment and responded during these 5 days, 18% presented with a melanotic tumour diagnosed by the dermatologist. Mean patient age was 52.0 Ϯ 17.3 years, with more women than men (56.8% vs 43.2%). A total of 41.9% had tumours discovered more than 5 years before and for 23.3% the melanotic tumour had been discovered more recently (less than a year ago). Fifteen percent of patients with a melanotic tumour also presented with a concomitant dermatological condition. The evaluation of stress via the self-questionnaire evidenced a self-perceived stress level of 8.8 Ϯ 4.0. Patients who had suffered from dermatosis for more than 5 years had a self-perceived stress level of 9.2 Ϯ 4.4 vs 8.9 Ϯ 3.5 in patients with a more recent skin condition (5 years or less). QoL evaluated using the SF12 showed a change in the mental component outcome with a score of 43.0 Ϯ 9.9 and a physical component score of 48.2 Ϯ 9.4. The SF12 mental component score was 45.0 Ϯ 9.3 in patients with dermatosis arising within the last 5 years vs 40.3 Ϯ 10.2 in patients with skin conditions of longer duration. CONCLUSIONS: The mental health status is more impaired for patients whose melanotic tumour had been discovered more than 5 years before than for those with a more recent tumour (p = 0.05). The findings of this study on patients with melanotic tumours, a subject seldom discussed in the literature, encourages us to investigate further.
PSS47 ATOPIC DERMATITIS AND THERMAL THERAPY: EVALUATION IN CHILDREN UNDER 15
Boussetta S, Taieb C Pierre Fabre, Boulogne, France OBJECTIVES: To evaluate the quality of life of the children treated at the Avène hydrotherapy center and that of their parents. METHODS: The quality of life of the children was evaluated using the CDLQI (Children's Dermatology Life Quality Index) and a generic scale (SF-12) was used. The questionnaires were filled in by one of the 2 parents: when the child arrived at the Avène hydrotherapy center (consultation on arrival), at the end of the thermal therapy (week 3) but also at 3 and 6 months. RESULTS: Our sample involved 237 subjects on arrival, with an average age of 10.2 Ϯ 3.2, 86.3% atopic and 10.7% with psoriasis. In 89% of cases it was the mother who accompanied the child. The average age was respectively 10.1 Ϯ 3.2 years for the children suffering from atopic dermatitis versus 11.3 Ϯ 2.8 years for the psoriasis patients. For the atopic children, there was a significant improvement in the CDLQI score at 3 weeks, sustained improvement at 3 months and perpetuation of the effect at 6 months. Regarding the SF-12, the results are organised into 2 scores: mental (MCS-12) and physi-
